IPOs are back, it seems. Caris Life Sciences is planning to go public under the ticker CAI, raising over $400 million dollars at a valuation of $5 billion. Caris claims they're an AI company, but are they really using their big data to its fullest potential? In this video, we'll compare Caris to a company we've analyzed previously: Tempus AI (TEM) and see how they differ. Spoiler alert: one actually seems to be using AI, while the other isn't.

Stay informed with our free disruptive technology investing newsletter, Nanalyze Weekly. Sign up now at https://www.nanalyze.com/nanalyze-weekly/. This episode is pulled from a YouTube presentation. View the original presentation at https://youtu.be/0Y7Tm9-WhTU.